ITN Business features Bioneer’s CosmeRNA

Source: ITN Business (external media)

A recent article published by ITN Business highlights the growing attention toward Bioneer’s CosmeRNA, an innovative cosmetic formulation that aims to support visible hair health in adults with androgenetic alopecia.

The article introduces CosmeRNA’s RNA-based approach, which focuses on modulating local cellular pathways in the scalp without systemic hormone alteration. According to the coverage, the technology is based on a Self-Assembled Micelle inhibitory RNA (SAMiRNA) designed to influence receptor expression directly at the hair follicle.

The feature also discusses Bioneer’s biotechnology background and ongoing industry recognition, noting that CosmeRNA has been showcased in industry settings as a novel cosmetic solution in hair care.

While external reporting suggests potential benefits for hair shedding and overall hair appearance, individual outcomes may vary. The editorial overview reflects available media reporting and does not constitute medical advice.

Read the full article:
Revolutionising Hair Care for Androgenetic Alopecia with Advanced Cosmetic Formulations – Bioneer’s CosmeRNA (ITN Business)

This journal entry references content published by a third-party media outlet and provides a summarised editorial overview for informational purposes only. It is not intended to diagnose, treat, cure, or prevent any health condition.

Latest Stories

View all

New York Post highlights cutting-edge hair care and treatment innovation in South Korea

New York Post highlights cutting-edge hair care and treatment innovation in South Korea

New York Post highlights cutting-edge hair care and treatment innovation in South Korea Source: New York Post (external media) A recent feature published by the New York Post explores how South Korea is emerging as a leading hub for advanced...

Read moreabout New York Post highlights cutting-edge hair care and treatment innovation in South Korea

Clinical Trial Evidence (RCT): CosmeRNA ARI in European Androgenetic Alopecia

Clinical Trial Evidence (RCT): CosmeRNA ARI in European Androgenetic Alopecia

A 2025 clinical research article published in Clinical and Experimental Dermatology and Therapies reports the results of a six-month, double-blind, randomized, placebo-controlled trial evaluating CosmeRNA ARI in adults with androgenetic alopecia in Germany.

Read moreabout Clinical Trial Evidence (RCT): CosmeRNA ARI in European Androgenetic Alopecia

EADV Congress 2025 – Hair and Nail Disorders Abstract Book

EADV Congress 2025 – Hair and Nail Disorders Abstract Book

A clinical research abstract presented at the EADV Congress 2025 reported findings from a randomised, double-blind, placebo-controlled study investigating an androgen-receptor-regulating topical approach in women with female pattern hair loss.

Read moreabout EADV Congress 2025 – Hair and Nail Disorders Abstract Book